Repurposing of Various Current Medicines as Radioprotective Agents


Citar

Texto integral

Resumo

Background: The side effects of ionising radiation include skin changes, dry mouth, hair loss, low blood count, and the mutagenic effect on normal cells when utilized in radiotherapy for cancer treatment. These radiations can cause damage to the cell membrane, lipids, proteins, and DNA and generate free radicals. Evidence reports stated that radiotherapy accounts for 17-19% of secondary malignancies, labelling this treatment option a double-edged sword.

Objective: Radioprotective molecules are used for mitigating radiotherapy's side effects. These agents show free radical scavenging, antioxidant, collagen synthesis inhibition, protease inhibition, immune stimulation, increased cytokine production, electron transfer, and toxicity reduction properties. The most frequently used amifostine has an array of cancer applications, showing multitarget action as nephroprotective to cisplatin and reducing the chances of xerostomia. Many other agents, such as metformin, edaravone, mercaptopropionylglycine, in specific diseases, such as diabetes, cerebral infarction, cystinuria, have shown radioprotective action. This article will discuss potentially repurposed radioprotectors that can be used in the clinical setting, along with a brief discussion on specific synthetic agents like amifostine and PrC-210.

Methods: Rigorous literature search using various electronic databases, such as PubMed, ScienceDirect, Scopus, EMBASE, Bentham Science, Cochrane Library, etc., was made. Peer-review research and review papers were selected, studied, reviewed, and analysed.

Conclusion: Safety and risk-free treatment can be guaranteed with the repurposed agents. Agents like metformin, captopril, nifedipine, simvastatin, and various others have shown potent radioprotective action in various studies. This review compiled repurposed synthetic radioprotective agents.

Sobre autores

Rajwinder Kaur

Chitkara College of Pharmacy,, Chitkara University

Autor responsável pela correspondência
Email: info@benthamscience.net

Damanpreet Lang

Chitkara College of Pharmacy,, Chitkara University,

Email: info@benthamscience.net

Harwinder Singh

Chitkara College of Pharmacy,, Chitkara University

Email: info@benthamscience.net

Arpita Arora

Chitkara College of Pharmacy,, Chitkara University,

Email: info@benthamscience.net

Nikhil Garg

Chitkara College of Pharmacy,, Chitkara Universi

Email: info@benthamscience.net

Balraj Saini

Chitkara College of Pharmacy,, Chitkara University

Email: info@benthamscience.net

Bibliografia

  1. Zhou, R.; Si, J.; Zhang, H.; Wang, Z.; Li, J.; Zhou, X.; Gan, L.; Liu, Y. The effects of X-ray radiation on the eye development of zebrafish. Hum. Exp. Toxicol., 2014, 33(10), 1040-1050. doi: 10.1177/0960327114522278 PMID: 24522107
  2. Holley, A.K.; Miao, L.; St Clair, D.K.; St Clair, W.H. Redox-modulated phenomena and radiation therapy: The central role of superoxide dismutases. Antioxid. Redox Signal., 2014, 20(10), 1567-1589. doi: 10.1089/ars.2012.5000 PMID: 24094070
  3. Zakariya, N.I.; Kahn, M.T. Benefits and biological effects of ionizing radiation. Sch. Acad. J. Biosci., 2014, 2(9), 583-591.
  4. Koukourakis, M.I. Radiation damage and radioprotectants: New concepts in the era of molecular medicine. Br. J. Radiol., 2012, 85(1012), 313-330. doi: 10.1259/bjr/16386034 PMID: 22294702
  5. Roychoudhuri, R.; Evans, H.; Robinson, D.; Møller, H. Radiation-induced malignancies following radiotherapy for breast cancer. Br. J. Cancer, 2004, 91(5), 868-872. doi: 10.1038/sj.bjc.6602084 PMID: 15292931
  6. Favier, O.; Heutte, N.; Stamatoullas-Bastard, A.; Carde, P.; Van't Veer, M.B.; Aleman, B.M.; Noordijk, E.M.; Thomas, J.; Fermé, C.; Henry-Amar, M. European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Survival after Hodgkin lymphoma: Causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer, 2009, 115(8), 1680-1691. doi: 10.1002/cncr.24178 PMID: 19208428
  7. Travis, L.B.; Rabkin, C.S.; Brown, L.M.; Allan, J.M.; Alter, B.P.; Ambrosone, C.B.; Begg, C.B.; Caporaso, N.; Chanock, S.; DeMichele, A.; Figg, W.D.; Gospodarowicz, M.K.; Hall, E.J.; Hisada, M.; Inskip, P.; Kleinerman, R.; Little, J.B.; Malkin, D.; Ng, A.K.; Offit, K.; Pui, C.H.; Robison, L.L.; Rothman, N.; Shields, P.G.; Strong, L.; Taniguchi, T.; Tucker, M.A.; Greene, M.H. Cancer survivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J. Natl. Cancer Inst., 2006, 98(1), 15-25. doi: 10.1093/jnci/djj001 PMID: 16391368
  8. Fowler, J.F. Review: Total doses in fractionated radiotherapy--implications of new radiobiological data. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 1984, 46(2), 103-120. doi: 10.1080/09553008414551181 PMID: 6381354
  9. Boerma, M.; van der Wees, C.G.; Vrieling, H.; Svensson, J.P.; Wondergem, J.; van der Laarse, A.; Mullenders, L.H.; van Zeeland, A.A. Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genomics, 2005, 6(1), 6. doi: 10.1186/1471-2164-6-6 PMID: 15656902
  10. Tsoutsou, P.G.; Koukourakis, M.I. Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66(5), 1281-1293. doi: 10.1016/j.ijrobp.2006.08.058 PMID: 17126203
  11. Ilnytskyy, Y.; Koturbash, I.; Kovalchuk, O. Radiation-induced bystander effects in vivo are epigenetically regulated in a tissue-specific manner. Environ. Mol. Mutagen., 2009, 50(2), 105-113. doi: 10.1002/em.20440 PMID: 19107897
  12. Hall, E.J.; Hei, T.K. Genomic instability and bystander effects induced by high-LET radiation. Oncogene, 2003, 22(45), 7034-7042. doi: 10.1038/sj.onc.1206900 PMID: 14557808
  13. Nosengo, N. Can you teach old drugs new tricks? Nature, 2016, 534(7607), 314-316. doi: 10.1038/534314a PMID: 27306171
  14. Hernandez, J.J.; Pryszlak, M.; Smith, L.; Yanchus, C.; Kurji, N.; Shahani, V.M.; Molinski, S.V. Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front. Oncol., 2017, 7, 273. doi: 10.3389/fonc.2017.00273 PMID: 29184849
  15. Ondetti, M.A.; Rubin, B.; Cushman, D.W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science, 1977, 196(4288), 441-444. doi: 10.1126/science.191908 PMID: 191908
  16. Williams, G.H. Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med., 1988, 319(23), 1517-1525. doi: 10.1056/NEJM198812083192305 PMID: 3054561
  17. Martin, M.F.; Surrall, K.E.; McKenna, F.; Dixon, J.S.; Bird, H.A.; Wright, V. Captopril: A new treatment for rheumatoid arthritis? Lancet, 1984, 1(8390), 1325-1328. doi: 10.1016/S0140-6736(84)91821-X PMID: 6145028
  18. Przyklenk, K; Kloner, RA Relationships between structure and effects of ACE inhibitors: Comparative effects in myocardial ischaemic/reperfusion injury. Br. J. Clin. Pharmacol., 1989, 28(Suppl. 2), 167S-175S.
  19. Parving, H.H.; Hommel, E.; Smidt, U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ, 1988, 297(6656), 1086-1091. doi: 10.1136/bmj.297.6656.1086 PMID: 3143437
  20. Cohen, E.P.; Fish, B.L.; Moulder, J.E. Treatment of radiation nephropathy with captopril. Radiat. Res., 1992, 132(3), 346-350. doi: 10.2307/3578243 PMID: 1475357
  21. Aruoma, O.I.; Akanmu, D.; Cecchini, R.; Halliwell, B. Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species. Chem. Biol. Interact., 1991, 77(3), 303-314. doi: 10.1016/0009-2797(91)90039-A PMID: 1849048
  22. Yoon, S.C.; Park, J.M.; Jang, H.S.; Shinn, K.S.; Bahk, Y.W. Radioprotective effect of captopril on the mouse jejunal mucosa. Int. J. Radiat. Oncol. Biol. Phys., 1994, 30(4), 873-878. doi: 10.1016/0360-3016(94)90363-8 PMID: 7960990
  23. Fantone, J.C.; Schrier, D.; Weingarten, B. Inhibition of vascular permeability changes in rats by captopril. J. Clin. Invest., 1982, 69(6), 1207-1211. doi: 10.1172/JCI110559 PMID: 6282931
  24. Phillips, T.L. Sensitizers and protectors in clinical oncology. Semin. Oncol., 1981, 8(1), 65-82. PMID: 6264627
  25. Moulder, J.E.; Fish, B.L. Age dependence of radiation nephropathy in the rat. Radiat. Res., 1997, 147(3), 349-353. doi: 10.2307/3579343 PMID: 9052682
  26. Cohen, E.P.; Fish, B.L.; Moulder, J.E. Successful brief captopril treatment in experimental radiation nephropathy. J. Lab. Clin. Med., 1997, 129(5), 536-547. doi: 10.1016/S0022-2143(97)90008-1 PMID: 9142050
  27. Ward, W.F.; Molteni, A.; Ts'ao, C.H.; Hinz, J.M. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int. J. Radiat. Oncol. Biol. Phys., 1990, 19(6), 1405-1409. doi: 10.1016/0360-3016(90)90351-J PMID: 2262365
  28. Mukherjee, S.K.; Goel, H.C.; Pant, K.; Jain, V. Preventation of radiation induced taste aversion in rats. Indian J. Exp. Biol., 1997, 35, 233-235.
  29. Griffin, K.A.; Picken, M.M.; Bakris, G.L.; Bidani, A.K. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int., 1999, 55(5), 1849-1860. doi: 10.1046/j.1523-1755.1999.00434.x PMID: 10231447
  30. Muruganandham, M.; Kasiviswanathan, A.; Jagannathan, N.R.; Raghunathan, P.; Jain, P.C.; Jain, V. Diltiazem enhances tumor blood flow: MRI study in a murine tumor. Int. J. Radiat. Oncol. Biol. Phys., 1999, 43(2), 413-421. doi: 10.1016/S0360-3016(98)00403-9 PMID: 10030270
  31. Floersheim, G.L. Calcium antagonists protect mice against lethal doses of ionizing radiation. Br. J. Radiol., 1992, 65(779), 1025-1029. doi: 10.1259/0007-1285-65-779-1025 PMID: 1450817
  32. Floersheim, G.L. Radioprotective effects of calcium antagonists used alone or with other types of radioprotectors. Radiat. Res., 1993, 133(1), 80-87. doi: 10.2307/3578260 PMID: 8434117
  33. Floersheim, G.L.; Racine, C. Calcium antagonist radioprotectors do not reduce radiotherapy efficacy in three human tumor xenografts. Stranhlentheroncol., 1995, 171(7), 403-407.
  34. Bolli, R.; Triana, F.; Jeroudi, M.O. Postischemic mechanical and vascular dysfunction (myocardial "stunning" and microvascular "stunning") and the effects of calcium-channel blockers on ischemia/reperfusion injury. Clin. Cardiol., 1989, 12(7)(Suppl. 3), III16-III25. PMID: 2691139
  35. Opie, L.H. Reperfusion injury and its pharmacologic modification. Circulation, 1989, 80(4), 1049-1062. doi: 10.1161/01.CIR.80.4.1049 PMID: 2571429
  36. Ip, J.H.; Levin, R.I. Myocardial preservation during ischemia and reperfusion. Am. Heart J., 1988, 115(5), 1094-1104. doi: 10.1016/0002-8703(88)90082-8 PMID: 3284312
  37. Janero, D.R.; Burghardt, B.; Lopez, R. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem. Pharmacol., 1988, 37(21), 4197-4203. doi: 10.1016/0006-2952(88)90116-5 PMID: 3190757
  38. Nayler, W.G.; Liu, J.J.; Panagiotopoulos, S. Nifedipine and experimental cardioprotection. Cardiovasc. Drugs Ther., 1990, 4(S5)(Suppl. 5), 879-885. doi: 10.1007/BF02018286 PMID: 2076394
  39. Watts, J.A.; Norris, T.A.; London, R.E.; Steenbergen, C.; Murphy, E. Effects of diltiazem on lactate, ATP, and cytosolic free calcium levels in ischemic hearts. J. Cardiovasc. Pharmacol., 1990, 15(1), 44-49. doi: 10.1097/00005344-199001000-00007 PMID: 1688981
  40. Koller, P.T.; Bergmann, S.R. Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. Circ. Res., 1989, 65(3), 838-846. doi: 10.1161/01.RES.65.3.838 PMID: 2766494
  41. Nunia, V.; Sancheti, G.; Goyal, P.K. Protection of Swiss albino mice against whole-body gamma irradiation by diltiazem. Br. J. Radiol., 2007, 80(950), 77-84. doi: 10.1259/bjr/41714035 PMID: 17068014
  42. Bailey, C.J.; Turner, R.C. Metformin. N. Engl. J. Med., 1996, 334(9), 574-579. doi: 10.1056/NEJM199602293340906 PMID: 8569826
  43. Najafi, M.; Cheki, M.; Rezapoor, S.; Geraily, G.; Motevaseli, E.; Carnovale, C.; Clementi, E.; Shirazi, A. Metformin: Prevention of genomic instability and cancer: A review. Mutat. Res., 2018, 827, 1-8. doi: 10.1016/j.mrgentox.2018.01.007 PMID: 29502733
  44. Yang, Y.; Li, B.; Liu, C.; Chuai, Y.; Lei, J.; Gao, F.; Cui, J.; Sun, D.; Cheng, Y.; Zhou, C.; Cai, J. Hydrogen-rich saline protects immunocytes from radiation-induced apoptosis. Med. Sci. Monit., 2012, 18(4), BR144-BR148. doi: 10.12659/MSM.882616 PMID: 22460088
  45. Chuai, Y.; Qian, L.; Sun, X.; Cai, J. Molecular hydrogen and radiation protection. Free Radic. Res., 2012, 46(9), 1061-1067. doi: 10.3109/10715762.2012.689429 PMID: 22537465
  46. Gómez-García, A.; Martínez Torres, G.; Ortega-Pierres, L.E.; Rodríguez-Ayala, E.; Álvarez-Aguilar, C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev. Esp. Cardiol., 2007, 60(12), 1242-1249. PMID: 18082089
  47. Shin, H.S.; Ko, J.; Kim, D.A.; Ryu, E.S.; Ryu, H.M.; Park, S.H.; Kim, Y.L.; Oh, E.S.; Kang, D.H. Metformin ameliorates the phenotype transition of peritoneal mesothelial cells and peritoneal fibrosis via a modulation of oxidative stress. Sci. Rep., 2017, 7(1), 5690. doi: 10.1038/s41598-017-05836-6 PMID: 28720775
  48. Bułdak, Ł.; Łabuzek, K.; Bułdak, R.J.; Kozłowski, M.; Machnik, G.; Liber, S.; Suchy, D.; Duława-Bułdak, A.; Okopień, B. Metformin affects macrophages' phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. Pharmacol. Rep., 2014, 66(3), 418-429. doi: 10.1016/j.pharep.2013.11.008 PMID: 24905518
  49. Bikas, A.; Van Nostrand, D.; Jensen, K.; Desale, S.; Mete, M.; Patel, A.; Wartofsky, L.; Vasko, V.; Burman, K.D. Metformin attenuates 131I-induced decrease in peripheral blood cells in patients with differentiated thyroid cancer. Thyroid, 2016, 26(2), 280-286. doi: 10.1089/thy.2015.0413 PMID: 26649977
  50. Cohen, E.P.; Fish, B.L.; Irving, A.A.; Rajapurkar, M.M.; Shah, S.V.; Moulder, J.E. Radiation nephropathy is not mitigated by antagonists of oxidative stress. Radiat. Res., 2009, 172(2), 260-264. doi: 10.1667/RR1739 PMID: 19630531
  51. Gauter-Fleckenstein, B.; Fleckenstein, K.; Owzar, K.; Jiang, C.; Rebouças, J.S.; Batinic-Haberle, I.; Vujaskovic, Z. Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage. Free Radic. Biol. Med., 2010, 48(8), 1034-1043. doi: 10.1016/j.freeradbiomed.2010.01.020 PMID: 20096348
  52. Jiang, J.; Belikova, N.A.; Hoye, A.T.; Zhao, Q.; Epperly, M.W.; Greenberger, J.S.; Wipf, P.; Kagan, V.E. A mitochondria-targeted nitroxide/hemigramicidin S conjugate protects mouse embryonic cells against gamma irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70(3), 816-825. doi: 10.1016/j.ijrobp.2007.10.047 PMID: 18262096
  53. Mahmood, J.; Jelveh, S.; Calveley, V.; Zaidi, A.; Doctrow, S.R.; Hill, R.P. Mitigation of lung injury after accidental exposure to radiation. Radiat. Res., 2011, 176(6), 770-780. doi: 10.1667/RR2562.1 PMID: 22013884
  54. Mahmood, J.; Jelveh, S.; Zaidi, A.; Doctrow, S.R.; Medhora, M.; Hill, R.P. Targeting the renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int. J. Radiat. Oncol. Biol. Phys., 2014, 89(4), 722-728. doi: 10.1016/j.ijrobp.2014.03.048 PMID: 24867538
  55. Mahmood, J.; Jelveh, S.; Zaidi, A.; Doctrow, S.R.; Hill, R.P. Mitigation of radiation-induced lung injury with EUK-207 and genistein: Effects in adolescent rats. Radiat. Res., 2013, 179(2), 125-134. doi: 10.1667/RR2954.1 PMID: 23237541
  56. Wang, J.; Wang, Y.; Han, J.; Mei, H.; Yu, D.; Ding, Q.; Zhang, T.; Wu, G.; Peng, G.; Lin, Z. Metformin attenuates radiation-induced pulmonary fibrosis in a murine model. Radiat. Res., 2017, 188(1), 105-113. doi: 10.1667/RR14708.1 PMID: 28437189
  57. Medhora, M.; Gao, F.; Jacobs, E.R.; Moulder, J.E. Radiation damage to the lung: Mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology, 2012, 17(1), 66-71. doi: 10.1111/j.1440-1843.2011.02092.x PMID: 22023053
  58. Kim, J.M.; Yoo, H.; Kim, J.Y.; Oh, S.H.; Kang, J.W.; Yoo, B.R.; Han, S.Y.; Kim, C.S.; Choi, W.H.; Lee, E.J.; Byeon, H.J.; Lee, W.J.; Lee, Y.S.; Cho, J. Metformin alleviates radiation-induced skin fibrosis via the down regulation of FOXO3. Cell. Physiol. Biochem., 2018, 48(3), 959-970. doi: 10.1159/000491964 PMID: 30036874
  59. Cheki, M.; Shirazi, A.; Mahmoudzadeh, A.; Bazzaz, J.T.; Hosseinimehr, S.J. The radioprotective effect of metformin against cytotoxicity and genotoxicity induced by ionizing radiation in cultured human blood lymphocytes. Mutat. Res., 2016, 809, 24-32. doi: 10.1016/j.mrgentox.2016.09.001 PMID: 27692296
  60. Bagheri, H.; Rezapoor, S.; Najafi, M.; Safar, H.; Shabeeb, D.; Cheki, M.; Shekarchi, B.; Motevaseli, E. Metformin protects the rat small intestine against radiation enteritis. Jundishapur J. Nat. Pharm. Prod., 2019, 14(4)e67352 doi: 10.5812/jjnpp.67352
  61. Hockerman, G.H.; Peterson, B.Z.; Johnson, B.D.; Catterall, W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol., 1997, 37, 361-396. doi: 10.1146/annurev.pharmtox.37.1.361 PMID: 9131258
  62. Shridi, F.; Robak, J. The influence of calcium channel blockers on superoxide anions. Pharmacol. Res. Commun., 1988, 20(1), 13-21. doi: 10.1016/S0031-6989(88)80603-9 PMID: 2836871
  63. Ondrias, K.; Misík, V.; Gergel, D.; Stasko, A. Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. Biochim. Biophys. Acta, 1989, 1003(3), 238-245. doi: 10.1016/0005-2760(89)90228-2 PMID: 2545261
  64. Finkelstein, E. Nifedipine for radiation oesophagitis. Lancet, 1986, 1(8491), 1205-1206. doi: 10.1016/S0140-6736(86)91178-5 PMID: 2871434
  65. Carlson, A.P.; Hänggi, D.; Macdonald, R.L.; Shuttleworth, C.W. Nimodipine reappraised: An old drug with a future. Curr. Neuropharmacol., 2020, 18(1), 65-82. doi: 10.2174/1570159X17666190927113021 PMID: 31560289
  66. Agnoli, A. The classification of calcium antagonists by the WHO expert committee: Relevance in neurology. Cephalalgia, 1988, 8(8_suppl)(Suppl. 8), 7-10. doi: 10.1177/03331024880080S802 PMID: 3180202
  67. Monzani, D.; Genovese, E.; Pini, L.A.; Di Berardino, F.; Alicandri Ciufelli, M.; Galeazzi, G.M.; Presutti, L. Nimodipine in otolaryngology: From past evidence to clinical perspectives. Acta Otorhinolaryngol. Ital., 2015, 35(3), 135-145. PMID: 26246657
  68. Hydman, J.; Björck, G.; Persson, J.K.; Zedenius, J.; Mattsson, P. Diagnosis and prognosis of iatrogenic injury of the recurrent laryngeal nerve. Ann. Otol. Rhinol. Laryngol., 2009, 118(7), 506-511. doi: 10.1177/000348940911800709 PMID: 19708490
  69. Guntinas-Lichius, O.; Martinez-Portillo, F.; Lebek, J.; Angelov, D.N.; Stennert, E.; Neiss, W.F. Floersheim. J. Neurocytol., 1997, 26(4), 241-248. doi: 10.1023/A:1018592215557 PMID: 9192289
  70. Nègre-Salvayre, A.; Fitoussi, G.; Troly, M.; Salvayre, R. Comparative cytoprotective effect of dihydropyridine calcium channel blockers against the toxicity of oxidized low density lipoprotein for cultured lymphoid cells. Biochem. Pharmacol., 1992, 44(12), 2379-2386. doi: 10.1016/0006-2952(92)90683-A PMID: 1472103
  71. Tong, J.; Li, J.; Zhang, Q.S.; Yang, J.K.; Zhang, L.; Liu, H.Y.; Liu, Y.Z.; Yuan, J.W.; Su, X.M.; Zhang, X.X.; Jiao, B.H. Delayed cognitive deficits can be alleviated by calcium antagonist nimodipine by downregulation of apoptosis following whole brain radiotherapy. Oncol. Lett., 2018, 16(2), 2525-2532. doi: 10.3892/ol.2018.8968 PMID: 30013647
  72. Bitto, A.; Minutoli, L.; Altavilla, D.; Polito, F.; Fiumara, T.; Marini, H.; Galeano, M.; Calò, M.; Lo Cascio, P.; Bonaiuto, M.; Migliorato, A.; Caputi, A.P.; Squadrito, F. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Pharmacol. Res., 2008, 57(2), 159-169. doi: 10.1016/j.phrs.2008.01.005 PMID: 18316203
  73. Nielsen, S.F.; Nordestgaard, B.G.; Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med., 2012, 367(19), 1792-1802. doi: 10.1056/NEJMoa1201735 PMID: 23134381
  74. Ludman, A.; Venugopal, V.; Yellon, D.M.; Hausenloy, D.J. Statins and cardioprotection-more than just lipid lowering? Pharmacol. Ther., 2009, 122(1), 30-43. doi: 10.1016/j.pharmthera.2009.01.002 PMID: 19318042
  75. Zhou, Q.; Liao, J.K. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ. J., 2010, 74(5), 818-826. doi: 10.1253/circj.CJ-10-0110 PMID: 20424337
  76. Fritz, G. Targeting the mevalonate pathway for improved anticancer therapy. Curr. Cancer Drug Targets, 2009, 9(5), 626-638. doi: 10.2174/156800909789057033 PMID: 19508172
  77. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14(1), 37-44. doi: 10.1016/j.molmed.2007.11.004 PMID: 18068482
  78. Hallahan, D.; Kuchibhotla, J.; Wyble, C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res., 1996, 56(22), 5150-5155. PMID: 8912850
  79. Quist-Paulsen, P. Statins and inflammation: An update. Curr. Opin. Cardiol., 2010, 25(4), 399-405. doi: 10.1097/HCO.0b013e3283398e53 PMID: 20421792
  80. Zhao, H.; Liao, Y.; Minamino, T.; Asano, Y.; Asakura, M.; Kim, J.; Asanuma, H.; Takashima, S.; Hori, M.; Kitakaze, M. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens. Res., 2008, 31(10), 1977-1987. doi: 10.1291/hypres.31.1977 PMID: 19015605
  81. Fitzgerald, J.P.; Chou, S.Y.; Franco, I.; Mooppan, U.M.; Kim, H.; Saini, R.; Gulmi, F.A. Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases. J. Urol., 2009, 182(4)(Suppl.), 1860-1868. doi: 10.1016/j.juro.2009.04.086 PMID: 19692013
  82. Mahmoudi, M.; Gorenne, I.; Mercer, J.; Figg, N.; Littlewood, T.; Bennett, M. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ. Res., 2008, 103(7), 717-725. doi: 10.1161/CIRCRESAHA.108.182899 PMID: 18723444
  83. Mathew, B.; Huang, Y.; Jacobson, J.R.; Berdyshev, E.; Gerhold, L.M.; Wang, T.; Moreno-Vinasco, L.; Lang, G.; Zhao, Y.; Chen, C.T.; LaRiviere, P.J.; Mauceri, H.; Sammani, S.; Husain, A.N.; Dudek, S.M.; Natarajan, V.; Lussier, Y.A.; Weichselbaum, R.R.; Garcia, J.G. Simvastatin attenuates radiation-induced murine lung injury and dysregulated lung gene expression. Am. J. Respir. Cell Mol. Biol., 2011, 44(3), 415-422. doi: 10.1165/rcmb.2010-0122OC PMID: 20508068
  84. Hahn, S.M.; Tochner, Z.; Krishna, C.M.; Glass, J.; Wilson, L.; Samuni, A.; Sprague, M.; Venzon, D.; Glatstein, E.; Mitchell, J.B. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res., 1992, 52(7), 1750-1753. PMID: 1551104
  85. Mitchell, J.B.; DeGraff, W.; Kaufman, D.; Krishna, M.C.; Samuni, A.; Finkelstein, E.; Ahn, M.S.; Hahn, S.M.; Gamson, J.; Russo, A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys., 1991, 289(1), 62-70. doi: 10.1016/0003-9861(91)90442-L PMID: 1654848
  86. Mitchell, J.B.; Russo, A.; Kuppusamy, P.; Krishna, M.C. Radiation, radicals, and images. Ann. N. Y. Acad. Sci., 2000, 899(1), 28-43. doi: 10.1111/j.1749-6632.2000.tb06174.x PMID: 10863527
  87. Xavier, S.; Yamada, K.; Samuni, A.M.; Samuni, A.; DeGraff, W.; Krishna, M.C.; Mitchell, J.B. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim. Biophys. Acta, 2002, 1573(2), 109-120. doi: 10.1016/S0304-4165(02)00339-2 PMID: 12399020
  88. Goffman, T.; Cuscela, D.; Glass, J.; Hahn, S.; Krishna, C.M.; Lupton, G.; Mitchell, J.B. Topical application of nitroxide protects radiation-induced alopecia in guinea pigs. Int. J. Radiat. Oncol. Biol. Phys., 1992, 22(4), 803-806. doi: 10.1016/0360-3016(92)90528-P PMID: 1544853
  89. Hahn, S.M.; Krishna, M.C.; DeLuca, A.M.; Coffin, D.; Mitchell, J.B. Evaluation of the hydroxylamine tempol-H as an in vivo radioprotector. Free Radic. Biol. Med., 2000, 28(6), 953-958. doi: 10.1016/S0891-5849(00)00176-3 PMID: 10802227
  90. Mitchell, J.B.; Samuni, A.; Krishna, M.C.; DeGraff, W.G.; Ahn, M.S.; Samuni, U.; Russo, A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry, 1990, 29(11), 2802-2807. doi: 10.1021/bi00463a024 PMID: 2161256
  91. DeGraff, W.G.; Krishna, M.C.; Kaufman, D.; Mitchell, J.B. Nitroxide-mediated protection against x-ray- and neocarzinostatin-induced DNA damage. Free Radic. Biol. Med., 1992, 13(5), 479-487. doi: 10.1016/0891-5849(92)90142-4 PMID: 1459474
  92. Vitolo, J.M.; Cotrim, A.P.; Sowers, A.L.; Russo, A.; Wellner, R.B.; Pillemer, S.R.; Mitchell, J.B.; Baum, B.J. The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin. Cancer Res., 2004, 10(5), 1807-1812. doi: 10.1158/1078-0432.CCR-03-0194 PMID: 15014035
  93. Guo, X.; Chen, S.; Zhang, Z.; Dobrovolsky, V.N.; Dial, S.L.; Guo, L.; Mei, N. Reactive oxygen species and c-Jun N-terminal kinases contribute to TEMPO-induced apoptosis in L5178Y cells. Chem. Biol. Interact., 2015, 235, 27-36. doi: 10.1016/j.cbi.2015.04.009 PMID: 25882087
  94. Yang, S.G.; Park, H.J.; Kim, J.W.; Jung, J.M.; Kim, M.J.; Jegal, H.G.; Kim, I.S.; Kang, M.J.; Wee, G.; Yang, H.Y.; Lee, Y.H.; Seo, J.H.; Kim, S.U.; Koo, D.B. Mito-TEMPO improves development competence by reducing superoxide in preimplantation porcine embryos. Sci. Rep., 2018, 8(1), 10130. doi: 10.1038/s41598-018-28497-5 PMID: 29973637
  95. Michalowski, A.S. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol., 1994, 33(2), 139-157. doi: 10.3109/02841869409098397 PMID: 8204269
  96. Laube, M.; Kniess, T.; Pietzsch, J. Development of antioxidant COX-2 inhibitors as radioprotective agents for radiation therapy-A hypothesis-driven review. Antioxidants, 2016, 5(2), 14. doi: 10.3390/antiox5020014 PMID: 27104573
  97. Saha, D.; Choy, H. Potential for combined modality therapy of cyclooxygenase inhibitors and radiation. Prog. Exp. Tumor Res., 2003, 37, 193-209. doi: 10.1159/000071374 PMID: 12795056
  98. Furuta, Y.; Hunter, N.; Barkley, T., Jr; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res., 1988, 48(11), 3008-3013. PMID: 3365690
  99. Nicolopoulos, N.; Mantidis, A.; Stathopoulos, E.; Papaodysseas, S.; Kouvaris, J.; Varveris, H.; Papavasiliou, C. Prophylactic administration of indomethacin for irradiation esophagitis. Radiother. Oncol., 1985, 3(1), 23-25. doi: 10.1016/S0167-8140(85)80005-0 PMID: 3883441
  100. Pillsbury, H.C., III; Webster, W.P.; Rosenman, J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch. Otolaryngol. Head Neck Surg., 1986, 112(5), 552-553. doi: 10.1001/archotol.1986.03780050076013 PMID: 3513801
  101. Lee, T.K.; Stupans, I. Radioprotection: The non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. J. Pharm. Pharmacol., 2002, 54(11), 1435-1445. doi: 10.1211/00223570254 PMID: 12495545
  102. Hofer, M.; Pospíšil, M.; Hoferová, Z.; Weiterová, L.; Komůrková, D. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: A review. Molecules, 2012, 17(5), 5615-5625. doi: 10.3390/molecules17055615 PMID: 22576231
  103. Tochner, Z.; Barnes, M.; Mitchell, J.B.; Orr, K.; Glatstein, E.; Russo, A. Protection by indomethacin against acute radiation esophagitis. Digestion, 1990, 47(2), 81-87. doi: 10.1159/000200480 PMID: 2292356
  104. Rose, P.G.; Halter, S.A.; Su, C.M. The effect of indomethacin on acute radiation induced gastrointestinal injury: A morphologic study. J. Surg. Oncol., 1992, 49(4), 231-238. doi: 10.1002/jso.2930490406 PMID: 1556867
  105. Mitchell, J.A.; Warner, T.D. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol., 1999, 128(6), 1121-1132. doi: 10.1038/sj.bjp.0702897 PMID: 10578123
  106. Akarca, U.S. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr. Pharm. Des., 2005, 11(14), 1779-1793. doi: 10.2174/1381612053764904 PMID: 15892675
  107. Liu, L.; Song, J. Voltammetric determination of mefenamic acid at lanthanum hydroxide nanowires modified carbon paste electrodes. Anal. Biochem., 2006, 354(1), 22-27. doi: 10.1016/j.ab.2006.04.015 PMID: 16707085
  108. Moghaddam, A.B.; Mohammadi, A.; Fathabadi, M. Application of carbon nanotube-graphite mixture for the determination of diclofenac sodium in pharmaceutical and biological samples. Pharm. Anal. Acta, 2012, 3(5), 1-6. doi: 10.4172/2153-2435.1000161
  109. Maffei Facino, R.; Carini, M.; Aldini, G.; Saibene, L.; Macciocchi, A. Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int. J. Tissue React., 1993, 15(6), 225-234. PMID: 8088944
  110. Mouithys-Mickalad, A.M.; Zheng, S.X.; Deby-Dupont, G.P.; Deby, C.M.; Lamy, M.M.; Reginster, J.Y.; Henrotin, Y.E. In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radic. Res., 2000, 33(5), 607-621. doi: 10.1080/10715760000301131 PMID: 11200092
  111. Rojo, C.; Álvarez-Figueroa, M.J.; Soto, M.; Cañete, A.; Pessoa-Mahana, D.; López-Alarcón, C. Scavenging activity of diclofenac: Interaction with ABTS radical cation and peroxyl radicals. J. Chil. Chem. Soc., 2009, 54(1), 58-62. doi: 10.4067/S0717-97072009000100014
  112. Thanagari, B.S.; Fefar, D.T.; Prajapati, K.S.; Jivani, B.M.; Thakor, K.B.; Patel, J.H.; Ghodasara, D.; Joshi, B.; Undhad, V. Haemato-biochemical alterations induced by diclofenac sodium toxicity in Swiss Albino mice. Vet. World, 2012, 5(7), 417-419. doi: 10.5455/vetworld.2012.417-419
  113. Labenz, J.; Blum, A.L.; Bolten, W.W.; Dragosics, B.; Rösch, W.; Stolte, M.; Koelz, H.R. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: A randomised, double blind, placebo controlled, clinical trial. Gut, 2002, 51(3), 329-335. doi: 10.1136/gut.51.3.329 PMID: 12171952
  114. Bojanowska-Czajka, A.; Kciuk, G.; Gumiela, M.; Borowiecka, S.; Nałęcz-Jawecki, G.; Koc, A.; Garcia-Reyes, J.F.; Ozbay, D.S.; Trojanowicz, M. Analytical, toxicological and kinetic investigation of decomposition of the drug diclofenac in waters and wastes using gamma radiation. Environ. Sci. Pollut. Res. Int., 2015, 22(24), 20255-20270. doi: 10.1007/s11356-015-5236-6 PMID: 26308920
  115. Schmidt, M.; Sørensen, H.T.; Pedersen, L. Diclofenac use and cardiovascular risks: Series of nationwide cohort studies. BMJ, 2018, 362, k3426. doi: 10.1136/bmj.k3426 PMID: 30181258
  116. Alok, A.; Agrawala, P.K. Repurposing sodium diclofenac as a radiation countermeasure agent: A cytogenetic study in human peripheral blood lymphocytes. Mutat. Res., 2020, 856-857503220 doi: 10.1016/j.mrgentox.2020.503220 PMID: 32928367
  117. Nagata, H.; Sugahara, T.; Tanaka, T. Radiation protection by 2-mercaptopropionylglycine in mice. J. Radiat. Res. (Tokyo), 1972, 13(3), 163-166. doi: 10.1269/jrr.13.163 PMID: 4643890
  118. Hikita, M.; Horikawa, M.; Mori, T. Analyses of radioprotective action and cytotoxicity of various sulfhydryl compounds in cultured mouse L cells. J. Radiat. Res. (Tokyo), 1975, 16(3), 162-172. doi: 10.1269/jrr.16.162 PMID: 1195186
  119. Kawasaki, S. Protective effect of various thiol compounds on radiation-induced mitotic delay in cultured mammalian cells (L-5). Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 1977, 32(6), 577-581. doi: 10.1080/09553007714551361 PMID: 304050
  120. Saharan, B.R.; Devi, P.U. Radiation protection of mouse testes with 2-mercaptopropionylglycine. J. Radiat. Res. (Tokyo), 1977, 18(4), 308-316. doi: 10.1269/jrr.18.308 PMID: 609062
  121. Saini, M.R.; Saharan, B.R.; Bhartiya, H.C.; Devi, P.U. Radiation protection of mouse liver by 2-mercaptopropionylglycine. J. Radiat. Res. (Tokyo), 1977, 18(3), 206-210. doi: 10.1269/jrr.18.206 PMID: 926066
  122. Saini, M.R.; Devi, P.U.; Yadav, S.S. Radiation protection of bone marrow lymphocytes by 2-mercaptopropionylglycine (MPG). Experientia, 1978, 34(12), 1627-1628. doi: 10.1007/BF02034716 PMID: 729737
  123. Saini, M.R.; Devi, P.U. Modification of radiation-induced spleen weight changes in mice by 2-mercaptopropionylglycine. Experientia, 1979, 35(12), 1628-1629. doi: 10.1007/BF01953233 PMID: 520478
  124. Devi, P.U.; Saharan, B.R. Chemical protection of mouse spermatocytes against gamma-rays with 2-mercaptopropionylglycine. Experientia, 1978, 34(1), 91-92. doi: 10.1007/BF01921922 PMID: 620750
  125. Devi, P.U.; Saini, M.R. Protection of mouse thymus against cobalt-60 radiation by 2-mercaptopropionylglycine (MPG). J. Radiat. Res. (Tokyo), 1977, 18(3), 211-224. doi: 10.1269/jrr.18.211 PMID: 926067
  126. Ayene, S.I.; Srivastava, P.N. Radioprotective effect of 2-mercaptopropionylglycine on radiation-induced microsomal lipid peroxidation. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 1985, 48(2), 197-205. doi: 10.1080/09553008514551191 PMID: 3926681
  127. Geist, J.R.; Kafrawy, A.H.; Shupe, R.E. The effect of MPG on radiation-induced odontogenic tissue metaplasia. Oral Surg. Oral Med. Oral Pathol., 1988, 65(1), 109-113. doi: 10.1016/0030-4220(88)90202-2 PMID: 3422391
  128. Hochstein, P.; Nordenbrand, K.; Ernster, L. Evidence for the involvement of iron in the ADP-activated peroxidation of lipids in microsomes and mitochondria. Biochem. Biophys. Res. Commun., 1964, 14(4), 323-328. doi: 10.1016/S0006-291X(64)80004-8 PMID: 4378683
  129. Motohashi, N.; Mori, I.; Sugiura, Y.; Tanaka, H. Modification of gamma-irradiation-induced change in myoglobin by alpha-mercaptopropionylglycine and its related compounds and the formation of sulfmyoglobin. Radiat. Res., 1981, 86(3), 479-487. doi: 10.2307/3575464 PMID: 7244123
  130. Sugiura, Y.; Tanaka, H. Iron-sulfide chelates of some sulfur-containing peptides as model complex of non-heme iron proteins. Biochem. Biophys. Res. Commun., 1972, 46(2), 335-340. doi: 10.1016/S0006-291X(72)80143-8 PMID: 5057878
  131. Kumar, A.; Uma Devi, P. MPG modification of the gamma ray sensitivity or ovarian follicles of mice. Radiobiol. Radiother. (Berl.), 1983, 24(2), 227-230. PMID: 6867302
  132. Mathur, S.; Bhartiya, H.C.; Routh, J. Nandchahal, Depletion of ovarian oocytes in sublethally exposed mice to gamma radiation and its modification by 2-mercaptopropionylglycine (MPG). Indian J. Exp. Biol., 1991, 29(1), 83-85. PMID: 1864626
  133. Abe, S.; Kirima, K.; Tsuchiya, K.; Okamoto, M.; Hasegawa, T.; Houchi, H.; Yoshizumi, M.; Tamaki, T. The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical. Chem. Pharm. Bull. (Tokyo), 2004, 52(2), 186-191. doi: 10.1248/cpb.52.186 PMID: 14758002
  134. Sasano, N.; Enomoto, A.; Hosoi, Y.; Katsumura, Y.; Matsumoto, Y.; Shiraishi, K.; Miyagawa, K.; Igaki, H.; Nakagawa, K. Free radical scavenger edaravone suppresses X-ray-induced apoptosis through p53 inhibition in MOLT-4 cells. J. Radiat. Res. (Tokyo), 2007, 48(6), 495-503. doi: 10.1269/jrr.07061 PMID: 17965547
  135. Jin, Q.; Cai, Y.; Li, S.; Liu, H.; Zhou, X.; Lu, C.; Gao, X.; Qian, J.; Zhang, J.; Ju, S.; Li, C. Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability. Theranostics, 2017, 7(4), 884-898. doi: 10.7150/thno.18219 PMID: 28382161
  136. Akaiwa, K.; Namekata, K.; Azuchi, Y.; Guo, X.; Kimura, A.; Harada, C.; Mitamura, Y.; Harada, T. Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Cell Death Dis., 2017, 8(7)e2934 doi: 10.1038/cddis.2017.341 PMID: 28703795
  137. Toyota, E.; Miyamoto, Y.; Imai, K.; Neishi, Y.; Kawamoto, T.; Okura, H.; Yoshida, K. Development of cardiac dysfunction induced by repetitive transient myocardial ischemia is inhibited by edaravone in conscious rats. Clin. Exp. Pharmacol. Physiol., 2009, 36(9), e20-e25. doi: 10.1111/j.1440-1681.2009.05178.x PMID: 19473343
  138. Zhang, W.W.; Bai, F.; Wang, J.; Zheng, R.H.; Yang, L.W.; James, E.A.; Zhao, Z.Q. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor. Drug Des. Devel. Ther., 2017, 11, 3019-3033. doi: 10.2147/DDDT.S144807 PMID: 29081650
  139. Kikuchi, K.; Takeshige, N.; Miura, N.; Morimoto, Y.; Ito, T.; Tancharoen, S.; Miyata, K.; Kikuchi, C.; Iida, N.; Uchikado, H.; Miyagi, N.; Shiomi, N.; Kuramoto, T.; Maruyama, I.; Morioka, M.; Kawahara, K.I. Beyond free radical scavenging: Beneficial effects of edaravone (radicut) in various diseases (Review). Exp. Ther. Med., 2012, 3(1), 3-8. doi: 10.3892/etm.2011.352 PMID: 22969835
  140. Zhang, M.; Teng, C.H.; Wu, F.F.; Ge, L.Y.; Xiao, J.; Zhang, H.Y.; Chen, D.Q. Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation. Exp. Ther. Med., 2019, 18(1), 467-474. doi: 10.3892/etm.2019.7632 PMID: 31281440
  141. Anzai, K.; Furuse, M.; Yoshida, A.; Matsuyama, A.; Moritake, T.; Tsuboi, K.; Ikota, N. in vivo radioprotection of mice by 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone; radicut), a clinical drug. J. Radiat. Res. (Tokyo), 2004, 45(2), 319-323. doi: 10.1269/jrr.45.319 PMID: 15304976
  142. Ishii, J.; Natsume, A.; Wakabayashi, T.; Takeuchi, H.; Hasegawa, H.; Kim, S.U.; Yoshida, J. The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress. Neurosci. Lett., 2007, 423(3), 225-230. doi: 10.1016/j.neulet.2007.07.029 PMID: 17709197
  143. Sasano, N.; Enomoto, A.; Hosoi, Y.; Katsumura, Y.; Matsumoto, Y.; Morita, A.; Shiraishi, K.; Miyagawa, K.; Igaki, H.; Nakagawa, K. Edaravone, a known free radical scavenger, enhances X-ray-induced apoptosis at low concentrations. Cancer Lett., 2010, 293(1), 52-57. doi: 10.1016/j.canlet.2009.12.020 PMID: 20092938
  144. Wang, G.H.; Jiang, Z.L.; Li, Y.C.; Li, X.; Shi, H.; Gao, Y.Q.; Vosler, P.S.; Chen, J. Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. J. Neurotrauma, 2011, 28(10), 2123-2134. doi: 10.1089/neu.2011.1939 PMID: 21732763
  145. Takizawa, Y.; Miyazawa, T.; Nonoyama, S.; Goto, Y.; Itoh, M. Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat. Pediatr. Res., 2009, 65(6), 636-641. doi: 10.1203/PDR.0b013e3181a16a9f PMID: 19247215
  146. Duntas, L.H. Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm. Metab. Res., 2009, 41(6), 443-447. doi: 10.1055/s-0029-1220724 PMID: 19418416
  147. Rafferty, T.S.; McKenzie, R.C.; Hunter, J.A.A.; Howie, A.F.; Arthur, J.R.; Nicol, F.; Beckett, G.J. Differential expression of selenoproteins by human skin cells and protection by selenium from UVB-radiation-induced cell death. Biochem. J., 1998, 332(Pt 1), 231-236. doi: 10.1042/bj3320231 PMID: 9576872
  148. Sill, R. Bedeutung von selen in pravention und komplementarer therapie. Pharm. Ztg., 1999, 144(32), 10-15.
  149. Mücke, R.; Büntzel, J.; Schönekaes, K.G.; Micke, O. Selen in der onkologie. wirklich ein "noli nocere"? Internist (Berl.), 2003, 44(2), 227-229. doi: 10.1007/s00108-002-0837-9 PMID: 12674743
  150. Micke, O.; Bruns, F.; Mücke, R.; Schäfer, U.; Glatzel, M.; DeVries, A.F.; Schönekaes, K.; Kisters, K.; Büntzel, J. Selenium in the treatment of radiation-associated secondary lymphedema. Int. J. Radiat. Oncol. Biol. Phys., 2003, 56(1), 40-49. doi: 10.1016/S0360-3016(02)04390-0 PMID: 12694822
  151. Coppes, R.P.; Vissink, A.; Konings, A.W. Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiother. Oncol., 2002, 63(3), 321-328. doi: 10.1016/S0167-8140(02)00129-9 PMID: 12142096
  152. Pontual, M.L.; Tuji, F.M.; Barros, S.P.; Bóscolo, F.N.; Novaes, P.D.; de Almeida, S.M. Ultrastructural evaluation of the radioprotective effect of sodium selenite on submandibular glands in rats. J. Appl. Oral Sci., 2007, 15(3), 162-168. doi: 10.1590/S1678-77572007000300003 PMID: 19089124
  153. Peter, B.; Van Waarde, M.A.; Vissink, A.; 's-Gravenmade, E.J.; Konings, A.W. Radiation-induced cell proliferation in the parotid and submandibular glands of the rat. Radiat. Res., 1994, 140(2), 257-265. doi: 10.2307/3578910 PMID: 7938475
  154. Lawrence, R.A.; Burk, R.F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem. Biophys. Res. Commun., 1976, 71(4), 952-958. doi: 10.1016/0006-291X(76)90747-6 PMID: 971321
  155. Sandström, B.E.; Grankvist, K.; Marklund, S.L. Selenite-induced increase in glutathione peroxidase activity protects human cells from hydrogen peroxide-induced DNA damage, but not from damage inflicted by ionizing radiation. Int. J. Radiat. Biol., 1989, 56(5), 837-841. doi: 10.1080/09553008914552121 PMID: 2573683
  156. Leccia, M.T.; Richard, M.J.; Beani, J.C.; Faure, H.; Monjo, A.M.; Cadet, J.; Amblard, P.; Favier, A. Protective effect of selenium and zinc on UV-A damage in human skin fibroblasts. Photochem. Photobiol., 1993, 58(4), 548-553. doi: 10.1111/j.1751-1097.1993.tb04930.x PMID: 8248330
  157. Chow, C.K.; Tappel, A.L. Response of glutathione peroxidase to dietary selenium in rats. J. Nutr., 1974, 104(4), 444-451. doi: 10.1093/jn/104.4.444 PMID: 4816929
  158. Hafeman, D.G.; Sunde, R.A.; Hoekstra, W.G. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J. Nutr., 1974, 104(5), 580-587. doi: 10.1093/jn/104.5.580 PMID: 4823943
  159. Meirow, D.; Nugent, D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update, 2001, 7(6), 535-543. doi: 10.1093/humupd/7.6.535 PMID: 11727861
  160. Sinha, P.; Kuruba, N. Premature ovarian failure. J. Obstet. Gynaecol., 2007, 27(1), 16-19. doi: 10.1080/01443610601016685 PMID: 17365451
  161. Sudour, H.; Chastagner, P.; Claude, L.; Desandes, E.; Klein, M.; Carrie, C.; Bernier, V. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int. J. Radiat. Oncol. Biol. Phys., 2010, 76(3), 867-873. doi: 10.1016/j.ijrobp.2009.04.012 PMID: 19632060
  162. Imam, S.Z.; Ali, S.F. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation. Brain Res., 2000, 855(1), 186-191. doi: 10.1016/S0006-8993(99)02249-0 PMID: 10650149
  163. Tsunoda, M.; Johnson, V.J.; Sharma, R.P. Increase in dopamine metabolites in murine striatum after oral exposure to inorganic but not organic form of selenium. Arch. Environ. Contam. Toxicol., 2000, 39(1), 32-37. doi: 10.1007/s002440010076 PMID: 10790499
  164. Trombly, D.J.; Woodruff, T.K.; Mayo, K.E. Suppression of notch signaling in the neonatal mouse ovary decreases primordial follicle formation. Endocrinology, 2009, 150(2), 1014-1024. doi: 10.1210/en.2008-0213 PMID: 18818300
  165. Allegra, M.; Reiter, R.J.; Tan, D.X.; Gentile, C.; Tesoriere, L.; Livrea, M.A. The chemistry of melatonin's interaction with reactive species. J. Pineal Res., 2003, 34(1), 1-10. doi: 10.1034/j.1600-079X.2003.02112.x PMID: 12485365
  166. Brzezinski, A. Melatonin in humans. N. Engl. J. Med., 1997, 336(3), 186-195. doi: 10.1056/NEJM199701163360306 PMID: 8988899
  167. Grant, S.G.; Melan, M.A.; Latimer, J.J.; Witt-Enderby, P.A. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev. Mol. Med., 2009, 11 e5 doi: 10.1017/S1462399409000982 PMID: 19193248
  168. Shabeeb, D.; Najafi, M.; Keshavarz, M.; Musa, A.E.; Hassanzadeh, G.; Hadian, M.R.; Shirazi, A. Recent finding in repair of the peripheral nerve lesions using pharmacological agents: Common methods for evaluating the repair process. Cent. Nerv. Syst. Agents Med. Chem., 2018, 18(3), 161-172. doi: 10.2174/1871524918666180830101953 PMID: 30160219
  169. Ianăş, O.; Olinescu, R.; Bădescu, I. Melatonin involvement in oxidative processes. Endocrinologie, 1991, 29(3-4), 147-153. PMID: 1821072
  170. Undeger, U.; Giray, B.; Zorlu, A.F.; Oge, K.; Baçaran, N. Protective effects of melatonin on the ionizing radiation induced DNA damage in the rat brain. Exp. Toxicol. Pathol., 2004, 55(5), 379-384. doi: 10.1078/0940-2993-00332 PMID: 15088639
  171. Roan, E.; Waters, C.M. What do we know about mechanical strain in lung alveoli? Am. J. Physiol. Lung Cell. Mol. Physiol., 2011, 301(5), L625-L635. doi: 10.1152/ajplung.00105.2011 PMID: 21873445
  172. Brennan, C.P.; Hendricks, G.L., III; El-Sheikh, T.M.; Mashaly, M.M. Melatonin and the enhancement of immune responses in immature male chickens. Poult. Sci., 2002, 81(3), 371-375. doi: 10.1093/ps/81.3.371 PMID: 11902414
  173. Mauriz, J.L.; Collado, P.S.; Veneroso, C.; Reiter, R.J.; González-Gallego, J. A review of the molecular aspects of melatonin's anti-inflammatory actions: Recent insights and new perspectives. J. Pineal Res., 2013, 54(1), 1-14. doi: 10.1111/j.1600-079X.2012.01014.x PMID: 22725668
  174. Ben-David, M.A.; Elkayam, R.; Gelernter, I.; Pfeffer, R.M. Melatonin for prevention of breast radiation dermatitis: A phase ii, prospective, double-blind randomized trial. Isr. Med. Assoc. J., 2016, 18(3-4), 188-192. PMID: 27228641
  175. Elangovan, N.; Chiou, T.J.; Tzeng, W.F.; Chu, S.T. Cyclophosphamide treatment causes impairment of sperm and its fertilizing ability in mice. Toxicology, 2006, 222(1-2), 60-70. doi: 10.1016/j.tox.2006.01.027 PMID: 16517039
  176. Hasinoff, B.B. Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol., 2006, 2(1), 15-20. doi: 10.2217/14796694.2.1.15 PMID: 16556068
  177. Langstein, H.N.; Duman, H.; Seelig, D.; Butler, C.E.; Evans, G.R. Retrospective study of the management of chemotherapeutic extravasation injury. Ann. Plast. Surg., 2002, 49(4), 369-374. doi: 10.1097/00000637-200210000-00006 PMID: 12370641
  178. Schrijvers, D.L. Extravasation: A dreaded complication of chemotherapy. Ann. Oncol., 2003, 14(Suppl. 3), iii26-iii30. doi: 10.1093/annonc/mdg744 PMID: 12821535
  179. Kassner, E. Evaluation and treatment of chemotherapy extravasation injuries. J. Pediatr. Oncol. Nurs., 2000, 17(3), 135-148. doi: 10.1053/jpon.2000.8063 PMID: 10944862
  180. Langer, S.W.; Sehested, M.; Jensen, P.B.; Buter, J.; Giaccone, G. Dexrazoxane in anthracycline extravasation. J. Clin. Oncol., 2000, 18(16), 3064. PMID: 10944144
  181. Swain, S.M.; Vici, P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. J. Cancer Res. Clin. Oncol., 2004, 130(1), 1-7. doi: 10.1007/s00432-003-0498-7 PMID: 14564513
  182. Wiseman, L.R.; Spencer, C.M. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs, 1998, 56(3), 385-403. doi: 10.2165/00003495-199856030-00009 PMID: 9777314
  183. Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 1999, 57(7), 727-741. doi: 10.1016/S0006-2952(98)00307-4 PMID: 10075079
  184. Hasinoff, B.B. Chemistry of dexrazoxane and analogues. Semin. Oncol., 1998, 25(4)(Suppl. 10), 3-9. PMID: 9768817
  185. Diop, N.K.; Vitellaro, L.K.; Arnold, P.; Shang, M.; Marusak, R.A. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem., 2000, 78(3), 209-216. doi: 10.1016/S0162-0134(00)00013-1 PMID: 10805177
  186. Hasinoff, B.B.; Schroeder, P.E.; Patel, D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol., 2003, 64(3), 670-678. doi: 10.1124/mol.64.3.670 PMID: 12920203
  187. Hasinoff, B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol., 2002, 2(2), 111-118. doi: 10.1385/CT:2:2:111 PMID: 12271154
  188. Langer, S.W.; Thougaard, A.V.; Sehested, M.; Jensen, P.B. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother. Pharmacol., 2006, 57(1), 125-128. doi: 10.1007/s00280-005-0022-7 PMID: 16001176
  189. El-Saghir, N.; Otrock, Z.; Mufarrij, A.; Abou-Mourad, Y.; Salem, Z.; Shamseddine, A.; Abbas, J. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol., 2004, 5(5), 320-321. doi: 10.1016/S1470-2045(04)01470-6 PMID: 15120669
  190. Jensen, J.N.; Lock-Andersen, J.; Langer, S.W.; Mejer, J. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand. J. Plast. Reconstr. Surg. Hand Surg., 2003, 37(3), 174-175. doi: 10.1080/02844310310007791 PMID: 12841619
  191. Bos, A.M.; van der Graaf, W.T.; Willemse, P.H. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncol., 2001, 40(4), 541-542. doi: 10.1080/028418601750288299 PMID: 11504316
  192. Andreassen, C.N.; Grau, C.; Lindegaard, J.C. Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol., 2003, 13(1), 62-72. doi: 10.1053/srao.2003.50006 PMID: 12520465
  193. Singh, V.K.; Seed, T.M. The efficacy and safety of amifostine for the acute radiation syndrome. Expert Opin. Drug Saf., 2019, 18(11), 1077-1090. doi: 10.1080/14740338.2019.1666104 PMID: 31526195
  194. Brizel, D.M.; Wasserman, T.H.; Henke, M.; Strnad, V.; Rudat, V.; Monnier, A.; Eschwege, F.; Zhang, J.; Russell, L.; Oster, W.; Sauer, R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol., 2000, 18(19), 3339-3345. doi: 10.1200/JCO.2000.18.19.3339 PMID: 11013273
  195. Grdina, D.J.; Nagy, B.; Hill, C.K.; Wells, R.L.; Peraino, C. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis, 1985, 6(6), 929-931. doi: 10.1093/carcin/6.6.929 PMID: 4006082
  196. Grdina, D.J.; Nagy, B.; Sigdestad, C.P. Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacol. Ther., 1988, 39(1-3), 21-25. doi: 10.1016/0163-7258(88)90035-6 PMID: 2849125
  197. Srinivasan, V.; Pendergrass, J.A., Jr; Kumar, K.S.; Landauer, M.R.; Seed, T.M. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int. J. Radiat. Biol., 2002, 78(6), 535-543. doi: 10.1080/095530002317577358 PMID: 12065057
  198. Tchanque-Fossuo, C.N.; Donneys, A.; Razdolsky, E.R.; Monson, L.A.; Farberg, A.S.; Deshpande, S.S.; Sarhaddi, D.; Poushanchi, B.; Goldstein, S.A.; Buchman, S.R. Quantitative histologic evidence of amifostine-induced cytoprotection in an irradiated murine model of mandibular distraction osteogenesis. Plast. Reconstr. Surg., 2012, 130(6), 1199-1207. doi: 10.1097/PRS.0b013e31826d2201 PMID: 22878481
  199. Kouvaris, J.R.; Kouloulias, V.E.; Vlahos, L.J. Amifostine: The first selective-target and broad-spectrum radioprotector. Oncologist, 2007, 12(6), 738-747. doi: 10.1634/theoncologist.12-6-738 PMID: 17602063
  200. Tchanque-Fossuo, C.N.; Donneys, A.; Deshpande, S.S.; Sarhaddi, D.; Nelson, N.S.; Monson, L.A.; Dahle, S.E.; Goldstein, S.A.; Buchman, S.R. Radioprotection with amifostine enhances bone strength and regeneration and bony union in a rat model of mandibular distraction osteogenesis. Ann. Plast. Surg., 2018, 80(2), 176-180. doi: 10.1097/SAP.0000000000001209 PMID: 28930778
  201. Peebles, D.D.; Soref, C.M.; Copp, R.R.; Thunberg, A.L.; Fahl, W.E. ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol. Radiat. Res., 2012, 178(1), 57-68. doi: 10.1667/RR2806.1 PMID: 22702647
  202. Copp, R.R.; Peebles, D.D.; Soref, C.M.; Fahl, W.E. Radioprotective efficacy and toxicity of a new family of aminothiol analogs. Int. J. Radiat. Biol., 2013, 89(7), 485-492. doi: 10.3109/09553002.2013.770579 PMID: 23369131
  203. Soref, C.M.; Hacker, T.A.; Fahl, W.E. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82(5), e701-e707. doi: 10.1016/j.ijrobp.2011.11.038 PMID: 22330992
  204. Jermusek, F., Jr; Benedict, C.; Dreischmeier, E.; Brand, M.; Uder, M.; Jeffery, J.J.; Ranallo, F.N.; Fahl, W.E. Significant suppression of CT radiation-induced DNA damage in normal human cells by the PrC-210 radioprotector. Radiat. Res., 2018, 190(2), 133-141. doi: 10.1667/RR14928.1 PMID: 29781766
  205. Bath, N.M.; Fahl, W.E.; Redfield, R.R. III Significant reduction of murine renal ischemia-reperfusion cell death using the immediate-acting PrC-210 reactive oxygen species scavenger. Transplant. Direct, 2019, 5(7)e469 doi: 10.1097/TXD.0000000000000909 PMID: 31334343
  206. Johnston, G.; Williams, R.L. 505 (b)(2) applications: History, science, and experience. Drug Inf. J., 2002, 36(2), 319-323. doi: 10.1177/009286150203600210
  207. Salminen, W.F.; Wiles, M.E.; Stevens, R.E. Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway. Drug Discov. Today, 2019, 24(1), 46-56. doi: 10.1016/j.drudis.2018.07.005 PMID: 30041014
  208. Verbaanderd, C.; Rooman, I.; Meheus, L.; Huys, I. On-label or off-label? overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front. Pharmacol., 2020, 10, 1664. doi: 10.3389/fphar.2019.01664 PMID: 32076405
  209. Man, S.; Yang, L.; Xiang, H.; Lu, G.; Wang, Y.; Liu, C.; Gao, W. Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats. Biomed. Pharmacother., 2020, 125109977 doi: 10.1016/j.biopha.2020.109977 PMID: 32032892
  210. Krishan, B.V.; Rao, C.H.; Kishore, V.S. Design and development of pulsatile drug delivery of diltiazem hydrochloride. Res. J. Pharm. Technol., 2020, 13(5), 2315-2320. doi: 10.5958/0974-360X.2020.00417.5
  211. Sharma, M.; Alam, S.; Kute, V.; Mazumder, M.A.; Meshram, H.S. Role of diltiazem in short-term outcome of live related renal transplant hypertensive recipients with non-surgical delayed graft function. Transplantation, 2020, 104(S3), S344. doi: 10.1097/01.tp.0000700272.47403.27
  212. Jia, Z.Q.; Li, S.Q.; Qiao, W.Q.; Xu, W.Z.; Xing, J.W.; Liu, J.T.; Song, H.; Gao, Z.Y.; Xing, B.W.; He, X.J. Ebselen protects mitochondrial function and oxidative stress while inhibiting the mitochondrial apoptosis pathway after acute spinal cord injury. Neurosci. Lett., 2018, 678, 110-117. doi: 10.1016/j.neulet.2018.05.007 PMID: 29733976
  213. Tankova, T. Current indications for metformin therapy. Rom. J. Intern. Med., 2003, 41(3), 215-225. PMID: 15526505
  214. Easterling, T.; Mundle, S.; Bracken, H.; Parvekar, S.; Mool, S.; Magee, L.A.; von Dadelszen, P.; Shochet, T.; Winikoff, B. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: An open-label, randomised controlled trial. Lancet, 2019, 394(10203), 1011-1021. doi: 10.1016/S0140-6736(19)31282-6 PMID: 31378394
  215. Maria, D.N.; Abd-Elgawad, A.H.; Soliman, O.A.; El-Dahan, M.S.; Jablonski, M.M. Nimodipine ophthalmic formulations for management of glaucoma. Pharm. Res., 2017, 34(4), 809-824. doi: 10.1007/s11095-017-2110-x PMID: 28155073
  216. Wolf, S.; Martin, H.; Landscheidt, J.F.; Rodiek, S.O.; Schürer, L.; Lumenta, C.B. Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm. Neurocrit. Care, 2010, 12(3), 346-351. doi: 10.1007/s12028-009-9317-6 PMID: 20033353
  217. Mu, H.; Wang, L. Efficacy of nimodipine plus yufeng ningxin tablets for patients with frequent migraine. Pharmacology, 2018, 102(1-2), 53-57. doi: 10.1159/000489314 PMID: 29879719
  218. Kastelein, J.J.; Akdim, F.; Stroes, E.S.; Zwinderman, A.H.; Bots, M.L.; Stalenhoef, A.F.; Visseren, F.L.; Sijbrands, E.J.; Trip, M.D.; Stein, E.A.; Gaudet, D.; Duivenvoorden, R.; Veltri, E.P.; Marais, A.D.; de Groot, E. Enhance Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med., 2008, 358(14), 1431-1443. doi: 10.1056/NEJMoa0800742 PMID: 18376000
  219. Ceriello, A.; Taboga, C.; Tonutti, L.; Quagliaro, L.; Piconi, L.; Bais, B.; Da Ros, R.; Motz, E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation, 2002, 106(10), 1211-1218. doi: 10.1161/01.CIR.0000027569.76671.A8 PMID: 12208795
  220. Obrosov, A.; Shevalye, H.; Coppey, L.J.; Yorek, M.A. Effect of tempol on peripheral neuropathy in diet-induced obese and high-fat fed/low-dose streptozotocin-treated C57Bl6/J mice. Free Radic. Res., 2017, 51(4), 360-367. doi: 10.1080/10715762.2017.1315767 PMID: 28376643
  221. Nagai, N.; Ito, Y.; Okamoto, N.; Shimomura, Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology, 2014, 319, 53-62. doi: 10.1016/j.tox.2014.02.012 PMID: 24598350
  222. Lucas, S. The pharmacology of indomethacin. Headache, 2016, 56(2), 436-446. doi: 10.1111/head.12769 PMID: 26865183
  223. Wiffen, P.J.; Xia, J. Systematic review of topical diclofenac for the treatment of acute and chronic musculoskeletal pain. Curr. Med. Res. Opin., 2020, 36(4), 637-650. doi: 10.1080/03007995.2020.1716703 PMID: 31944135
  224. Pak, C.Y.; Fuller, C.; Sakhaee, K.; Zerwekh, J.E.; Adams, B.V. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J. Urol., 1986, 136(5), 1003-1008. doi: 10.1016/S0022-5347(17)45188-3 PMID: 3534301
  225. Sawada, H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharmacother., 2017, 18(7), 735-738. doi: 10.1080/14656566.2017.1319937 PMID: 28406335
  226. Kieliszek, M.; Lipinski, B.; Błażejak, S. Application of sodium selenite in the prevention and treatment of cancers. Cells, 2017, 6(4), 39. doi: 10.3390/cells6040039 PMID: 29064404
  227. Elmegeed, G.A.; Baiuomy, A.R.; Abdel-Salam, O.M. Evaluation of the anti-inflammatory and anti-nociceptive activities of novel synthesized melatonin analogues. Eur. J. Med. Chem., 2007, 42(10), 1285-1292. doi: 10.1016/j.ejmech.2007.01.027 PMID: 17408809
  228. Cvetković, R.S.; Scott, L.J. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 2005, 65(7), 1005-1024. doi: 10.2165/00003495-200565070-00008 PMID: 15892593
  229. Obrador, E.; Salvador, R.; Villaescusa, J.I.; Soriano, J.M.; Estrela, J.M.; Montoro, A. Radioprotection and radiomitigation: From the bench to clinical practice. Biomedicines, 2020, 8(11), 461. doi: 10.3390/biomedicines8110461 PMID: 33142986

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2023